113 related articles for article (PubMed ID: 16192109)
1. Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates.
Komura H; Iwaki M
Xenobiotica; 2005 Jun; 35(6):575-87. PubMed ID: 16192109
[TBL] [Abstract][Full Text] [Related]
2. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
[TBL] [Abstract][Full Text] [Related]
3. Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes.
Rowland K; Ellis SW; Lennard MS; Tucker GT
Br J Clin Pharmacol; 1996 Sep; 42(3):390-3. PubMed ID: 8877032
[TBL] [Abstract][Full Text] [Related]
4. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
Gibbs JP; Hyland R; Youdim K
Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
[TBL] [Abstract][Full Text] [Related]
5. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
6. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.
Takashima T; Murase S; Iwasaki K; Shimada K
Drug Metab Pharmacokinet; 2005 Jun; 20(3):177-82. PubMed ID: 15988119
[TBL] [Abstract][Full Text] [Related]
8. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations.
Johnson JA; Burlew BS
Drug Metab Dispos; 1996 Mar; 24(3):350-5. PubMed ID: 8820427
[TBL] [Abstract][Full Text] [Related]
9. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Belpaire FM; Wijnant P; Temmerman A; Rasmussen BB; Brøsen K
Eur J Clin Pharmacol; 1998 May; 54(3):261-4. PubMed ID: 9681670
[TBL] [Abstract][Full Text] [Related]
10. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
[TBL] [Abstract][Full Text] [Related]
11. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Dorne JL; Walton K; Slob W; Renwick AG
Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.
Madani S; Paine MF; Lewis L; Thummel KE; Shen DD
Pharm Res; 1999 Aug; 16(8):1199-205. PubMed ID: 10468020
[TBL] [Abstract][Full Text] [Related]
13. Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.
Rabinovich-Guilatt L; Steiner L; Hallak H; Pastino G; Muglia P; Spiegelstein O
Br J Clin Pharmacol; 2017 Oct; 83(10):2214-2224. PubMed ID: 28449367
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.
Rowland K; Yeo WW; Ellis SW; Chadwick IG; Haq I; Lennard MS; Jackson PR; Ramsay LE; Tucker GT
Br J Clin Pharmacol; 1994 Jul; 38(1):9-14. PubMed ID: 7946944
[TBL] [Abstract][Full Text] [Related]
15. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
Ebner T; Eichelbaum M
Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
17. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.
Wu C; Jiang XL; Shen HW; Yu AM
Biochem Pharmacol; 2009 Sep; 78(6):617-24. PubMed ID: 19445902
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
Van LM; Swales J; Hammond C; Wilson C; Hargreaves JA; Rostami-Hodjegan A
Eur J Pharm Sci; 2007 May; 31(1):53-61. PubMed ID: 17387004
[TBL] [Abstract][Full Text] [Related]
20. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
Ewald AH; Maurer HH
Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
